LUCDLucid Diagnostics Inc. Common Stock

Revenue jumped 17% as company shifts focus to higher-reimbursement opportunities.

Lucid Diagnostics (NASDAQ:LUCD) is positioning its EsoGuard test as a non-invasive tool to identify Barrett’s Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a key Medicare coverage decision and expands relationships with commercial payers, the Department of Ve

Moby summary of PAVmed Inc.'s Q2 2026 earnings call

Moby summary of Lucid Diagnostics Inc.'s Q2 2026 earnings call

Lucid Diagnostics Inc (LUCD) reports 17% revenue growth and secures first LBM coverage policy, but faces persistent denial rates and cash burn challenges.

Lucid Diagnostics (NASDAQ:LUCD) reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while awaiting a Medicare draft local coverage determination, or LCD. Chief Executive Officer Dr. Lishan

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -50.00% and -1.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) delivered earnings and revenue surprises of +54.55% and +3.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences (PLSE) delivered earnings and revenue surprises of -16.13% and -38.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FocalTherics (FOCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Alphatec (ATEC) delivered earnings and revenue surprises of -22.22% and +1.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?